V. Richon

Molecular Biology · 2000–2013

A researcher in the Science corpus: 14 papers; trusts 2 researchers and is trusted by 5 researchers here, as inferred from the citation graph.

Subfields

• Molecular Biology — 101 citations into it; #6,977 of 17,773 by trust here, #2,582 by citations

Whom V. Richon trusts overall

Their strongest outbound trust, strongest first, inferred from their citations.

1. PA Marks

Who trusts V. Richon overall

1. PA Marks
2. S. Minucci
3. C. A. Dinarello
4. Manel Esteller
5. S. Baylin
6. Weisheng Xu
7. Ricky W. Johnstone
8. Jessica E. Bolden

Papers from V. Richon's perspective

Ordered by how strongly the researchers V. Richon trusts endorse each paper. Same corpus, a different order for every researcher.

1. The language of covalent histone modifications (Nature)
2. Histone deacetylases and cancer: causes and therapies (Nature Reviews. Cancer)
3. hDOT1L links histone methylation to leukemogenesis. (Cell)
4. The silencing protein SIR2 and its homologs are NAD-dependent protein deacetylases. (Proceedings of the National Academy of Sciences of the United States of America)
5. Acetylation: a regulatory modification to rival phosphorylation? (EMBO Journal)
6. MLL translocations, histone modifications and leukaemia stem-cell development (Nature Reviews. Cancer)
7. Phylogenetic classification of prokaryotic and eukaryotic Sir2-like proteins. (Biochemical and Biophysical Research Communications - BBRC)
8. Histone deacetylases induce angiogenesis by negative regulation of tumor suppressor genes (Nature Medicine)
9. SUZ12 is required for both the histone methyltransferase activity and the silencing function of the EED-EZH2 complex. (Molecules and Cells)
10. Mutations truncating the EP300 acetylase in human cancers (Nature Genetics)

Their papers

• Histone deacetylases and cancer: causes and therapies (2001) — 1,931 citations
• Selective Killing of Mixed Lineage Leukemia Cells by a Potent Small-Molecule DOT1L Inhibitor (2011) — 928 citations
• Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation. (2000) — 1,174 citations
• MLL-rearranged Leukemia is Dependent on Aberrant H3K79 Methylation by DOT1L (2011) — 883 citations
• Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). (2007) — 1,033 citations
• A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells. (2012) — 770 citations
• Coordinated activities of wild-type plus mutant EZH2 drive tumor-associated hypertrimethylation of lysine 27 on histone H3 (H3K27) in human B-cell lymphomas (2010) — 682 citations
• Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells. (2000) — 1,225 citations
• Histone deacetylase (HDAC) inhibitor activation of p21WAF1 involves changes in promoter-associated proteins, including HDAC1. (2004) — 600 citations
• Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of Huntington's disease (2003) — 860 citations
• Potent inhibition of DOT1L as treatment of MLL-fusion leukemia. (2013) — 684 citations
• Durable tumor regression in genetically altered malignant rhabdoid tumors by inhibition of methyltransferase EZH2 (2013) — 742 citations
• Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously. (2003) — 659 citations
• Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo. (2000) — 618 citations